In IMmotion151 cohort, we selected patients with metastatic ccRCC receiving first-line atezolizumab plus bevacizumab and grouped them into PHLDA2-H and PHLDA2-L subgroups. This evidence concerns the gene PHLDA2 and nonpapillary renal cell carcinoma.